Every material Form 8-K HARVARD BIOSCIENCE INC has filed with the SEC since June 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Harvard Bioscience furnished an August 2026 investor presentation under Regulation FD showing second-quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier. The company raised its full-year 2026 revenue growth guidance to 3% to 5% from 2% to 4%, but lowered its adjusted gross margin guidance to 57% to 59% from 58% to 60%. GAAP net loss widened to $2.9 million from $2.3 million, while adjusted EBITDA rose to $1.7 million from $1.5 million.
Q2 2026 revenue of $22.7 million, up from $20.5 million in Q2 2025
GAAP net loss of $2.9 million, compared with $2.3 million a year earlier
Adjusted EBITDA of $1.7 million, up from $1.5 million; adjusted EBITDA growth guidance for FY26 maintained at 6% to 10%
Q3 2026 revenue guidance of $21.0 million to $22.6 million
Harvard Bioscience reported second quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier, and raised its full-year 2026 revenue growth guidance to 3% to 5%. The company's GAAP net loss widened to $2.9 million from $2.3 million, so the sales gain came with a larger loss for shareholders.
Q2 2026 revenue of $22.7 million vs. $20.5 million in Q2 2025; foreign currency added about 1%
Q2 2026 net loss of $2.9 million vs. $2.3 million in Q2 2025; adjusted EBITDA rose to $1.7 million from $1.5 million
Full-year 2026 revenue growth guidance raised to 3% to 5%; adjusted gross margin target lowered to 57% to 59%
Third quarter 2026 revenue guidance of $21.0 million to $22.6 million
At its June 2, 2026 annual meeting, Harvard Bioscience stockholders approved an amended 2021 Incentive Plan that adds 400,000 shares for awards, and they approved an amendment to the Employee Stock Purchase Plan that increases its authorized shares. Stockholders also re-elected two directors, John Duke and Katherine A. Eade, to terms running to 2029, and ratified Grant Thornton LLP as auditor for 2026. The filing reports no financial results.
The incentive plan increase adds 400,000 shares; 646,520 shares were available for future awards as of December 31, 2025.
Votes for the incentive plan were 1,131,261, against were 680,030, and abstentions were 17,700.
John Duke and Katherine A. Eade were elected as Class II Directors for three-year terms ending in 2029.
Grant Thornton LLP was ratified as independent registered public accounting firm for fiscal 2026 with 2,781,705 votes for.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every HARVARD BIOSCIENCE INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →